The challenges of physiologically-based pharmacokinetic (PBPK) modelling and approaches to replacing the use of animals, in order to determine drug pharmacokinetics, are discussed. Reference is made to the limitations of in vivo animal studies in drug discovery. In particular, the ways in which animal studies contribute to drug attrition during the post-preclinical phase of testing are considered.
ThomasS. (2009). Physiologically-based simulation modelling for the reduction of animal use in the discovery of novel pharmaceuticals. ATLA37, 497–511.
2.
KolaI. & LandisJ. (2004). Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery3, 711–716.
3.
ThomasS. (2009). Physiologically-based simulation modelling for the reduction of animal use in the discovery of novel pharmaceuticals. ATLA37, 497–511.
4.
BrightmanF.A., LeahyD.E., SearleG.E. & ThomasS. (2006). Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metabolism & Disposition34, 94–101.
5.
CaldwellG.W., MasucciJ.A., YanZ. & HagemanW. (2004). Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in vivo rat data?European Journal of Drug Metabolism & Pharmacokinetics29, 133–143.
6.
WardK.W. & SmithB.R. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance. Drug Metabolism & Disposition32, 603–611.
7.
MahmoodI. (2002). Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabolism & Drug Interactions19, 49–64.
